复星医药：控股子公司复星医药产业与Sitala签订许可协议

Core Viewpoint - Fosun Pharma's subsidiary has entered into a licensing agreement with Sitala, granting Sitala global rights (excluding China) to develop, manufacture, and commercialize FXS6837 and related products [1] Group 1 - The agreement stipulates that Sitala will pay up to $190 million, which includes an upfront payment and milestone payments for development and commercialization [1]